IRADIMED CEO Roger E. Susi sold 7,500 shares indirectly through a trust for approximately $691,000 as part of a systematic Rule 10b5-1 plan. The sale represents routine liquidation rather than a negative signal, with the stock up 60.89% over the past year. The key investment variable is the adoption of the company's new infusion pump, with meaningful data expected by mid-2027.

Iradimed CEO Roger Susi sold 7,500 shares worth ~$694,125 on April 20-21, 2026, as part of a Rule 10b5-1 trading plan adopted in November 2025. The sale is not concerning as it follows a systematic pattern and Susi retains over 4 million shares. Iradimed's strong business performance—with 2025 sales up 14% to $83.8M and net income reaching $22.5M—has driven the stock up 78% over one year, though the elevated forward P/E of 42 suggests waiting for a price dip before buying.

IRADIMED CORPORATION announced its participation in the 38th Annual Roth Conference on March 22 and 24, 2026, at the Ritz-Carlton in Laguna Niguel, CA. CEO Roger Susi and CFO Jack Glenn will host one-on-one meetings with investors. The company is a leader in MRI-compatible medical devices, including its patented MRidium® IV infusion pump system and 3880 patient vital signs monitoring system.

Iradimed Corporation's stock surged 9.26% after reporting its 18th consecutive quarter of record revenue at $22.7 million (up 17% YoY) and beating adjusted net income estimates at $0.54 per share versus $0.48 expected. The medical device maker, which specializes in MRI-compatible infusion pump systems, launched a new product and raised its quarterly dividend from $0.17 to $0.20 per share. The company provided 2026 guidance of $91-96 million in revenue and $2.06-2.21 adjusted net income per share.

Baker Hughes, an energy technology company, has two segments: Oilfield Services & Equipment (OFSE) and Industrial & Energy Technology (IET). The report provides insights into the company's digital transformation strategies, innovation programs, and technology initiatives.

The global well intervention market is projected to reach USD 12.14 Billion by 2031, driven by new oilfield developments, rising energy demand, and the need to maintain the integrity of aging oil and gas wells. The market is expected to grow at a CAGR of 4.8% during the forecast period.

Trading to commence effective on the market open June 14, 2024 Trading to commence effective on the market open June 14, 2024

WINTER SPRINGS, Fla., April 25, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2024 first quarter financial results before the market opens on Thursday, May 2, 2024. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions.

IRADIMED CORPORATION To Participate at the 36th Annual Roth Conference

WINTER SPRINGS, Fla., Feb. 08, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) announced today its financial results for the three months and year ended December 31, 2023. The Company is a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only known provider of a non-magnetic intravenous (“IV”) infusion pump system, and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures.

WINTER SPRINGS, Fla., Feb. 01, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2023 fourth quarter financial results before the market opens on Thursday, February 8, 2024. Iradimed management will host a conference call the same day beginning at 9:00 a.m. Eastern Time to discuss those results and to answer questions.

IRADIMED CORPORATION Announces Participation in 42nd Annual J.P. Morgan Healthcare Conference